Skip to content
DataLookout
Menu

NCT06702449

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 43 words Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Trial sites expanded: 8 → 35 locations
    • Enrollment target: estimated 448 to confirmed 465
    • Primary and study completion dates: May 31, 2027 to May 3, 2027
    • Study description revised
  2. Minor Study sites: 2 to 8
    • Primary and study completion dates: Sep 2, 2027 to May 31, 2027
    v4
  3. Minor Primary and study completion dates: Jul 27, 2027 to Sep 2, 2027v3
  4. Notable Eligibility criteria expanded, about 22 words
    • Primary endpoints: 12 to 15
    • Study sites: 32 to 2
    • Primary and study completion dates: Aug 2, 2027 to Jul 27, 2027
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part 1 and 2: Number of participants reporting solicited administration site adverse events (AEs)
Timeframe: During the 7 days follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting solicited administration site AEs
Timeframe: During the 7 days follow-up period post-Dose 2 (study intervention administered at Day 61)
Part 1 and 2: Number of participants reporting solicited systemic AEs
Timeframe: During the 7 days follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting unsolicited AEs
Timeframe: During the 30 days follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting any immediate unsolicited AEs
Timeframe: During the 60 minutes follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting serious adverse events (SAEs)
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1 and 2: Number of participants reporting potential immune-mediated diseases (pIMDs) leading to study withdrawal
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1 and 2: Number of participants reporting medically-attended adverse events (MAAEs) leading to study withdrawal
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1 and 2: Number of participants reporting AEs leading to study withdrawal
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1: Number of participants with hematology or biochemistry abnormalities or changes in baseline value
Timeframe: At 7 days post-Dose 1 (Day 8) compared with baseline (pre-Dose 1, Day 1)
Part 2: Incidence rate (IR) of the first occurrence of a urine culture confirmed UTI due to E. coli in the investigational group compared to the IR in placebo group
Timeframe: From 14 days (Day 75) up to 12 months (Day 426) post-Dose 2

Secondary (2)

Part 2: IR of the total number of occurrences of urine culture confirmed UTIs due to E. coli in the investigational group compared to the IR in placebo group
Part 2: IR of the first occurrence of a urine culture confirmed UTI due to E. coli in the investigational group compared to the IR in placebo group

Arms and interventions

Part 1 Group A1/A2Experimental

Participants receive candidate UTI vaccine low dose formulation 1 or placebo on Day 1 and Day 61.

Part 1 Group B1/B2Experimental

Participants receive candidate UTI vaccine low dose formulation 2, or placebo on Day 1 and Day 61.

Part 1 Group C1/C2Experimental

Participants receive candidate UTI vaccine medium dose formulation 1, or placebo on Day 1 and Day 61.

Part 1 Group D1/D2Experimental

Participants receive candidate UTI vaccine medium dose formulation 2, or placebo on Day 1 and Day 61.

Part 1 Group E1/E2Experimental

Participants receive candidate UTI vaccine high dose formulation 1, or placebo on Day 1 and Day 61.

Part 1 Group F1/F2Experimental

Participants receive candidate UTI vaccine high dose formulation 2, or placebo on Day 1 and Day 61.

Part 2 Group 1Experimental

Participants receive the candidate UTI vaccine highest tolerated dose (HTD) formulation 2, tested in Part 1 of the study, on Day 1 and Day 61.

Part 2 Group 2Placebo comparator

Participants receive placebo on Day 1 and Day 61.

Combination products: Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo

Sites

35 sites in 6 countries

Spain 11, United States 9, Belgium 6, Argentina 4, South Africa 4, Puerto Rico 1